Industry Wire 270

May 7, 2025 Viktor Zarev 0 min read
  1. CMS suspends 8 MIPS improvement activities. 
  2. Scripps and Anthem Blue Cross reunite after 5 months out-of-network.
  3. Cleveland Clinic and Regent Surgical form ASC joint venture
  4. What drug tariffs could mean for UnitedHealth, CVS, and Centene.
  5. Medtech M&A sees fewer deals but more money in Q1.
  6. Northwell Health acquires Nuvance Health.
  7. Elevated medical costs continued to drag insurers in Q1 2025.
  8. HHS launches autism project using Medicare and Medicaid data.
  9. Hospitals and communities still struggling with Steward bankruptcy.
  10. Trump orders FDA to speed up building of new drug factories.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions February 19, 2026

Evolut Low Risk, A Tale of Two Outcomes February 19, 2026

We might need to reconsider the concept of a TAVR-first strategy for low-risk aortic stenosis patients, after extended results from the Evolut Low Risk trial showed that reintervention rates at seven years were considerably higher in TAVR recipients compared to surgical replacement. As has been the case for each yearly follow-up, the trial examined 1.4k […]

Heart Failure February 19, 2026

Rethinking Hyperkalemia Care in Patients With Heart Failure February 19, 2026

By Ravi Dhingra, MD, MPH, FACC, FAHASponsored By AstraZeneca Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is a cornerstone of heart failure (HF) management, yet concerns about hyperkalemia (HK) can limit its use.1 In chronic HF management, a long-term approach to addressing HK is an important consideration for healthcare providers. An observational study2 utilizing Optum’s de-identified Market Clarity Data […]

Cardiology Pharmaceuticals February 16, 2026

DAPT Drugs Matter to Diabetics with Multivessel CAD February 16, 2026

The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that ticagrelor isn’t equivalent to prasugrel in this complex patient group. The TUXEDO-2 trial enrolled 1.8k participants across 66 clinical sites in India and randomized patients undergoing PCI to […]